Oral Propranolol for Infantile Hemangiomas (NEJM Journal Club)

Oral Propranolol for Infantile Hemangiomas (NEJM Journal Club)

In this study, the authors show that oral propranolol effectively treats infantile hemangiomas in 60% of participants compared to 4% with placebo in a randomized controlled trial.

Summary Card

Level of Evidence: Randomized Controlled Trial

Background: Infantile hemangiomas are benign vascular tumors affecting 5-10% of infants. Oral propranolol is a potential treatment option.

Methods: A double-blind, randomized trial compared oral propranolol (3 mg/kg/day) to placebo in 460 infants with hemangioma.

Results: Propranolol achieved successful treatment in 60% of participants, compared to 4% in the placebo group.

Conclusion: Oral propranolol is an effective and well-tolerated treatment for infantile hemangiomas, but further research is needed for optimal treatment duration and long-term effects.

The complete journal club analysis is for thePlasticsPro users.

This section is for supporters of thePlasticsFella's mission

Join the club
Already have an account? Sign in
Great! Next, complete checkout for full access to thePlasticsFella.
Welcome back! You've successfully signed in.
You've successfully subscribed to thePlasticsFella.
Success! Your account is fully activated, you now have access to all content.
Success! Your billing info has been updated.
Your billing was not updated.